Acurx says Japan, Mexico patent offices grant new patents for DNA polymerase IIIC inhibitor antibiotics

ACXP•2026-08-12

Japan and Mexico patents expand Acurx’s portfolio

Acurx Pharmaceuticals said patent offices in Japan and Mexico have granted new patents covering its DNA polymerase IIIC inhibitor antibiotics across compositions, use, and formulations.

The company said its expanded portfolio now includes six U.S. patents and 10 international patents covering ibezapolstat and the ACX-375C program.

Ibezapolstat for C. difficile infection remains Phase 3 ready, contingent on financing.

Acurx says Japan, Mexico patent offices grant new patents for DNA polymerase IIIC inhibitor antibiotics

Japan and Mexico patents expand Acurx’s portfolio

Related News

Energy Fuels says Australian Strategic Materials shareholders back takeover scheme

EG Acquisition FY26 H1 net loss narrows 36.6% to $24.84 million; revenue rises 15.6% to $207.47 million

Alico CEO Kiernan to present at Midwest IDEAS investor conference

Capstone Holding Says Prior Financial Statements For 2025 Should Not Be Relied Upon - SEC Filing

Rimini Street names Keith Costello executive vice president, COO